Abiomed INC (ABMD) Holder Brown Capital Management LLC Has Trimmed Its Position by $61.20 Million as Stock Declined

ABIOMED, Inc. (NASDAQ:ABMD) LogoInvestors sentiment increased to 1.61 in Q2 2018. Its up 0.66, from 0.95 in 2018Q1. It increased, as 19 investors sold ABMD shares while 131 reduced holdings. 123 funds opened positions while 118 raised stakes. 36.14 million shares or 0.72% less from 36.41 million shares in 2018Q1 were reported. 65,531 were reported by Barclays Public Limited Company. Wilbanks Smith & Thomas Asset Limited has 0.07% invested in ABIOMED, Inc. (NASDAQ:ABMD). Bluemountain Capital Mngmt Limited Liability Com invested in 9,832 shares. Nomura reported 73,535 shares or 0.12% of all its holdings. 91,760 are held by Advisors Asset Management. 513 were reported by Two Sigma Ltd Liability Com. Coe Mgmt has invested 1.57% of its portfolio in ABIOMED, Inc. (NASDAQ:ABMD). Pictet Asset Mgmt Ltd invested in 0.02% or 21,900 shares. Hwg LP reported 195 shares stake. Conestoga Capital Advsr Llc reported 600 shares. The Virginia-based Virginia Retirement Et Al has invested 0.01% in ABIOMED, Inc. (NASDAQ:ABMD). Tiverton Asset Limited Liability accumulated 0.01% or 637 shares. Cornerstone Advsrs holds 4 shares or 0% of its portfolio. Credit Agricole S A owns 7,800 shares. Advisory Services Ltd Company, a Georgia-based fund reported 364 shares.

Since June 15, 2018, it had 0 insider buys, and 5 insider sales for $74.93 million activity. Greenfield Andrew J sold $2.10M worth of stock or 5,000 shares. Howley Michael G had sold 10,000 shares worth $4.33M. MINOGUE MICHAEL R had sold 105,000 shares worth $46.17 million on Thursday, June 21.

Brown Capital Management Llc decreased its stake in Abiomed Inc (ABMD) by 10.62% based on its latest 2018Q2 regulatory filing with the SEC. Brown Capital Management Llc sold 149,644 shares as the company’s stock declined 9.27% while stock markets rallied. The institutional investor held 1.26M shares of the health care company at the end of 2018Q2, valued at $515.31M, down from 1.41M at the end of the previous reported quarter. Brown Capital Management Llc who had been investing in Abiomed Inc for a number of months, seems to be less bullish one the $14.30 billion market cap company. The stock decreased 4.64% or $15.46 during the last trading session, reaching $317.52. About 467,881 shares traded. ABIOMED, Inc. (NASDAQ:ABMD) has risen 148.84% since December 8, 2017 and is uptrending. It has outperformed by 133.22% the S&P500.

Brown Capital Management Llc, which manages about $7.02B and $9.75 billion US Long portfolio, upped its stake in Vocera Communications Inc (NYSE:VCRA) by 1.02 million shares to 5.48M shares, valued at $163.88 million in 2018Q2, according to the filing. It also increased its holding in Teva Pharmaceutical Inds Ltd (NYSE:TEVA) by 151,895 shares in the quarter, for a total of 495,421 shares, and has risen its stake in Balchem Corp (NASDAQ:BCPC).

Analysts await ABIOMED, Inc. (NASDAQ:ABMD) to report earnings on February, 7. They expect $0.93 earnings per share, up 32.86 % or $0.23 from last year’s $0.7 per share. ABMD’s profit will be $41.89M for 85.35 P/E if the $0.93 EPS becomes a reality. After $0.81 actual earnings per share reported by ABIOMED, Inc. for the previous quarter, Wall Street now forecasts 14.81 % EPS growth.

More notable recent ABIOMED, Inc. (NASDAQ:ABMD) news were published by: Nasdaq.com which released: “Validea’s Top Five Healthcare Stocks Based On Motley Fool – 11/18/2018 – Nasdaq” on November 18, 2018, also Nasdaq.com with their article: “Factors of Influence in 2018, Key Indicators and Opportunity within The Middleby, Just Energy Group, Global Payments, VAREX IMAGING, ABIOMED, and SolarEdge Technologies — New Research Emphasizes Economic Growth – Nasdaq” published on November 29, 2018, Nasdaq.com published: “Wednesday Sector Leaders: Industrial, Healthcare – Nasdaq” on November 28, 2018. More interesting news about ABIOMED, Inc. (NASDAQ:ABMD) were released by: Nasdaq.com and their article: “Monday Sector Laggards: Technology & Communications, Healthcare – Nasdaq” published on November 19, 2018 as well as Nasdaq.com‘s news article titled: “Here’s Why You Should Invest in Abiomed (ABMD) Right Now – Nasdaq” with publication date: November 26, 2018.

ABIOMED, Inc. (NASDAQ:ABMD) Ratings Coverage

Among 2 analysts covering Abiomed (NASDAQ:ABMD), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Abiomed had 3 analyst reports since October 11, 2018 according to SRatingsIntel. The firm has “Overweight” rating by Morgan Stanley given on Wednesday, November 7. The firm has “Buy” rating by BTIG Research given on Friday, November 2. On Thursday, October 11 the stock rating was maintained by Morgan Stanley with “Equal-Weight”.

ABIOMED, Inc. (NASDAQ:ABMD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.